Search

Cancer, Health and Medicine, Oncology, Prostate Cancer, Prostatic Neoplasms, Therapy Keywords: Cancer; Health and Medicine; Oncology; Prostate Cancer; Prostatic Neoplasms; Therapy EN Cancer Health and Medicine Oncology Prostate Cancer Prostatic Neoplasms Therapy 2023 JAN 31 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Weekly -- Current study results on prostate cancer have been published. [Extracted from the article]

A recent study conducted at the University of Oklahoma Health Sciences Center focused on the use of mobile MRI-guided transurethral ultrasound ablation (TULSA) for prostate cancer treatment. The research highlighted the successful administration of TULSA by urologists in a mobile treatment center, showcasing promising outcomes and improvements in patient care. This innovative approach could potentially expand patient access to TULSA and improve treatment outcomes for prostate cancer patients. [Extracted from the article]

A patent has been issued for pharmaceutical compositions and combinations containing inhibitors of the androgen receptor, with a focus on treating various types of cancer. The patent discusses the role of androgens in prostate, breast, and ovarian cancers, as well as the development of treatments targeting the androgen receptor. The document outlines methods for treating cancer by administering specific compounds in combination with radiation therapy. For more detailed information, readers are encouraged to refer to the full patent document. [Extracted from the article]

The article discusses a newly launched clinical trial, NCT06636747, comparing high resolution diffusion weighted imaging (hrDWI) and conventional DWI in prostate cancer diagnosis. The study aims to improve image quality and lesion detection by increasing signal-to-noise ratio and contrast-to-noise ratio. The trial, conducted at The First Affiliated Hospital with Nanjing Medical University, focuses on evaluating the diagnostic accuracy of prostate cancer using hrDWI as an alternative to conventional DWI. The study is observational, recruiting male participants aged 55 years and older in China, with a completion date set for July 31, 2026. [Extracted from the article]

The article discusses the limitations of the radiotheranostic concept in neuroendocrine tumors due to lineage-dependent somatostatin receptor expression on hematopoietic stem and progenitor cells. It highlights the challenges in accurate dosimetry due to microscopic heterogeneity of radiopharmaceutical distribution and the high uptake of SSTR2-ligands by hematopoietic stem cells. The findings suggest that target expression heterogeneity can lead to underestimation of radiopharmaceutical toxicity, emphasizing the need for careful consideration in designing clinical trials for new radiopharmaceuticals. [Extracted from the article]

The article discusses a clinical trial, NCT06636123, focusing on the use of GZ17-6.02 to delay progression of castration-resistant prostate cancer. The trial aims to assess radiographic progression-free survival, biochemical response rate, duration of response, objective response rate, radiographic response duration, overall survival, safety, and tolerability of GZ17-6.02. The study involves men with advanced castration-resistant prostate cancer who have previously received androgen deprivation therapy and an androgen receptor pathway inhibitor. [Extracted from the article]

Researchers from Cedars Sinai Medical Center conducted a systematic scoping review on the use of wearable activity monitors for prostate cancer survivors. The study analyzed 44 articles published between 2012 and 2022, focusing on monitoring physical activity and sleep metrics outside clinical settings. The findings suggest that wearables are feasible for assessing daily activity and adherence to exercise interventions in clinical studies involving prostate cancer survivors. Further research is needed to explore the integration of wearables into routine clinical care and to deliver tailored interventions for this population. [Extracted from the article]

A recent study conducted by Northwestern Medicine in Chicago, Illinois, focused on the external validation of a multimodal artificial intelligence model for risk stratification in localized prostate cancer patients. The study validated the model's ability to predict distant metastasis and prostate cancer-specific mortality, showing promising results in improving prognostication for patient care. Funded by NIH National Cancer Institute, Pfizer, and Bristol-Myers Squibb, this research contributes to the advancement of AI technology in clinical trials and studies. [Extracted from the article]

Researchers at the Mayo Clinic in Rochester, Minnesota, have conducted a study on prostate cancer, specifically focusing on the role of the CENPK splice variant in response to the drug Abiraterone in metastatic castration-resistant prostate cancer. The study found that the CENPK-delta8 variant is linked to drug resistance through enhanced migration and proliferation, highlighting the importance of alternative splice variants in predicting drug response and improving individual therapeutic outcomes in precision medicine. This research was supported by the Department of Defense and the Mayo Clinic Centre For Individualized Medicine. [Extracted from the article]

A recent study conducted by the University of Hull in Kingston upon Hull, United Kingdom, explored the impact of physical activity and dietary behaviors on prostate cancer prevention and survivorship outcomes. Prostate cancer is the second most common cancer among men globally, with over 1.4 million new cases diagnosed each year. The research suggests that regular physical activity and nutritional interventions may improve survival outcomes and mitigate some adverse side effects of hormone treatments in men with prostate cancer. Further research is needed to enhance our understanding of the health effects of physical activity and nutrition in relation to prostate cancer prevention and survivorship. [Extracted from the article]

The article explores the explainability of a machine learning model for prostate cancer by evaluating feature maps to create visual interpretations. Four Residual Neural Networks were created to identify clinically significant prostate cancer on different datasets and training types, with results showing high co-localization rates with important feature maps. The study suggests that models trained on full cross-sectional pelvis images perform better in identifying abnormalities, indicating the potential usefulness of feature maps for model explainability in the future. [Extracted from the article]

A study examined the association between hormone therapy (HT) usage and major adverse cardiac events (MACE) in prostate cancer patients. The research, based on a diverse cohort of 5,156 participants, found that HT was linked to an increased risk of MACE in individuals with pre-existing dyslipidemia. The study suggests that risk stratification could aid in improving cardiovascular outcomes when determining treatment plans for prostate cancer patients. [Extracted from the article]

A study conducted in China aimed to determine the optimal screening interval for middle-aged and elderly Chinese males with baseline prostate-specific antigen (PSA) levels below 2.0 ng/mL. The research, conducted over an eight-year period, found that men aged 50-70 with baseline PSA levels below 2.0 ng/mL should undergo PSA retesting in the sixth year, while those aged 40-49 with the same baseline levels do not need PSA screening within eight years. The study identified specific criteria for prostate biopsy based on PSA levels and age groups, highlighting the importance of tailored screening approaches for different demographics. [Extracted from the article]

A recent study conducted by researchers at Fudan University Shanghai Cancer Center highlights the increasing incidence of prostate cancer in China compared to developed nations. The study emphasizes the importance of early diagnosis and standardized treatment for prostate cancer in China, with a focus on integrated treatment methods such as endocrine drugs, chemotherapy, targeted therapy, and immunotherapy. The Genitourinary Oncology Committee of the China Anti-Cancer Association has developed guidelines for the holistic integrative management of prostate cancer, which includes various aspects of diagnosis, treatment, and rehabilitation specific to the Chinese clinical practice. This guideline aims to standardize clinical practices and highlight Chinese characteristics in managing prostate cancer. [Extracted from the article]

A recent study from Beijing Sport University utilized Mendelian Randomization analysis to explore the potential causal relationship between light DIY activities and prostate cancer risk. The findings suggest that participation in light DIY activities may slightly increase the risk of prostate cancer. This research highlights the importance of considering the types and intensities of physical activities when making public health recommendations and personal lifestyle choices. For more information, the full article can be accessed in the American Journal of Men's Health. [Extracted from the article]

A recent study conducted at Emory University Hospital in Atlanta, Georgia, explored the safety and effectiveness of magnetic resonance imaging-guided cryoablation for prostate cancer metastatic lymph nodes. The research involved 46 patients who underwent 55 procedures, with promising results showing locoregional tumor control and decreased prostate-specific antigen levels. The study concluded that MR imaging-guided cryoablation is a safe and effective technique for treating metastatic prostate cancer in lymph nodes. For more information, the study can be found in the Journal of Vascular and Interventional Radiology. [Extracted from the article]

A recent study conducted by researchers at the Georgia Institute of Technology focused on the genetic architectures of prostate cancer susceptibility in Sub-Saharan Africa. The study utilized genomic data from various African countries to identify ancestry-specific genetic associations related to prostate cancer. The findings highlighted the importance of conducting genetic studies with diverse populations and emphasized the impact of population-specific risk variants on prostate cancer susceptibility in Africa. The research was funded by the U.S. Department of Health & Human Services and the National Institutes of Health. [Extracted from the article]

A recent study conducted at the University of Miami focused on metastatic hormone-sensitive prostate cancer (mHSPC) and the impact of HSD3B1 inheritance on patient outcomes. The research found that patients with low-volume mHSPC who inherited the adrenal-permissive HSD3B1 allele had better clinical progression-free survival and overall survival when treated with specific therapies. The study suggests that HSD3B1 genotype may play a role in prostate cancer mortality and could potentially be reversed pharmacologically. For more information, readers can refer to the Journal of Clinical Investigation. [Extracted from the article]

A recent study conducted at Fudan University Shanghai Cancer Center in China evaluated the efficacy and safety of enzalutamide versus placebo in Chinese men with metastatic hormone-sensitive prostate cancer. The study found that enzalutamide significantly reduced the hazard for prostate-specific antigen progression when combined with androgen deprivation therapy. Results from the China ARCHES trial were consistent with the global ARCHES study, indicating a positive impact of enzalutamide on prostate cancer treatment outcomes. For more information, the full article can be accessed for free at https://doi.org/10.1097/ju9.0000000000000198. [Extracted from the article]

Researchers from the University of California San Francisco (UCSF) have developed a machine learning model to predict lymph node metastasis in patients with prostate cancer. The model, called XGBoost, outperformed traditional tools like the Roach formula and MSKCC nomogram in predicting lymph node involvement. This study highlights the potential of machine learning to improve patient selection and outcomes in prostate cancer treatment. [Extracted from the article]

A recent study conducted at Xiangtan Central Hospital in China explored the predictive diagnostic value of mean platelet volume to platelet count ratio (PVI) and neutrophil-to-lymphocyte ratio (NLR) in the gray zone of prostate cancer with tPSA levels between 4 to 10 ng/mL. The study included 117 patients, with PVI and NLR identified as independent predictors for diagnosing prostate cancer in this gray zone. The research concluded that PVI and NLR have potential diagnostic value for prostate cancer in this specific context, potentially improving early screening outcomes. [Extracted from the article]

Researchers from Hangzhou First People's Hospital in China conducted a study to evaluate the effectiveness of using the PI-RADS v2.1 score in combination with quantitative parameters from DWI and DCE-MRI to differentiate between benign prostatic hyperplasia (BPH) and prostate cancer (PCa). The study analyzed data from 65 patients with prostate diseases and found that the PI-RADS v2.1 score, along with ADC, Ktrans, and Kep values, were significantly different between the BPH and PCa groups. The researchers concluded that these imaging tools and quantitative parameters can be valuable in distinguishing between BPH and PCa, with the combination of parameters enhancing diagnostic accuracy. [Extracted from the article]

A recent study conducted at the University of Zaragoza focused on the effects of PT-112, a small molecule, on human prostate cancer cell lines. The research found that PT-112 induced mitochondrial stress and immunogenic cell death in cancer cells, leading to anticancer immunity. This study sheds light on potential clinical applications of PT-112 in treating metastatic castration-resistant prostate cancer. For more information, the full article can be accessed in the Journal of Translational Medicine. [Extracted from the article]

A recent study conducted by researchers from the University of Virginia, Mount Sinai, the University of Michigan, and the University of Texas has shown promising results in treating prostate cancer using a new nanoparticle-based therapy. The therapy involves using gold nanoshells that can be targeted with near-infrared laser treatment to destroy cancerous tissue while preserving healthy cells. This innovative method, called nanoparticle-directed focal photothermal ablation, successfully eliminated cancerous cells in 73% of patients after 12 months, with no observed side effects and preservation of key quality-of-life factors. The study highlights the potential of interdisciplinary collaboration in advancing cancer treatment and improving patient outcomes. [Extracted from the article]

The article discusses the Chronic Radiation Induced Bowel Toxicity Study (CRIBS), a clinical trial investigating the effects of pelvic radiotherapy on the bowel microbiota in patients with prostate cancer. The study aims to analyze changes in bacteria in the bowel, urine, blood, and rectal swabs during radiotherapy treatment. Approximately 50 patients will be recruited over a two-year period from two sites in the UK. The study will collect longitudinal samples and health questionnaires to assess the impact of radiotherapy on the gut microbiota. [Extracted from the article]

A recent study by researchers at Duke Cancer Institute found that Black men with advanced prostate cancer have a higher chance of survival after immunotherapy treatment due to ancestral gene variants in immune responses. This connection was highlighted in the journal Cancer Research Communications. The study suggests that understanding ancestral differences in immune responses could help doctors identify patients who may benefit from immunotherapy, particularly sipuleucel-T. The research, funded by the National Institutes of Health and Dendreon Pharmaceuticals, sheds light on the importance of ancestry in immunotherapy responses for cancer patients. [Extracted from the article]

The article discusses a clinical trial, NCT06643962, focusing on the efficacy and safety of combining Venetoclax with intensive chemotherapy for patients with newly diagnosed acute myeloid leukemia and lower early peripheral blast clearance rates after standard induction therapy. The trial aims to evaluate outcomes such as complete remission rates, event-free survival, relapse-free survival, and overall survival. Eligibility criteria include age between 18-70, fitness for intensive chemotherapy, and specific health parameters. The study is not yet recruiting, with an enrollment target of 83 participants and a completion date of October 31, 2027. [Extracted from the article]

The article discusses the Hexosamine Biosynthetic Pathway's role in altering the cytoskeleton to modulate cell proliferation and migration in metastatic prostate cancer. It highlights the challenges posed by castration-resistant prostate cancer (CRPC) and the potential therapeutic implications of targeting the HBP pathway. The study suggests that inhibiting HBP could disrupt the cytoskeleton, leading to uncontrolled cell growth and migration, offering a novel approach for treating CRPC. The findings are based on a CRISPR-Cas9 knockout model of GNPNAT1 in CRPC cells, indicating the pathway's critical role in regulating cancer cell behavior. [Extracted from the article]

A study conducted in Jodhpur, India, aimed to establish age-specific PSA ranges in an Indian cohort to improve prostate cancer screening and diagnosis. The research found that PSA levels in the Indian population were lower compared to Western populations, but higher than some previous Indian studies, aligning with global trends. The study emphasized the importance of understanding the rising incidence of prostate cancer in India and cautioned against directly extrapolating Western data to the Indian population. [Extracted from the article]

Researchers at Antonius Hospital have conducted a study on the effects of co-treating advanced prostate cancer patients with androgen deprivation therapy (ADT) and the fetal estrogen estetrol (E4). The study found that ADT+E4 almost completely suppressed follicle-stimulating hormone (FSH) and decreased insulin-like growth factor-1 (IGF-1) levels, suggesting potential enhanced anti-cancer treatment efficacy. This research, funded by Pantarhei Oncology, provides valuable insights into the potential benefits of E4 therapy in prostate cancer treatment. For more information, the full article is available in the Journal of Clinical Medicine. [Extracted from the article]

Researchers from Oregon Health & Science University conducted a study comparing gene expression profiles in canine and human prostate cancers to identify mediators of castration resistance. They found that certain genes, such as ISG15 and AZGP1, were consistently up- and down-regulated in both species, suggesting a potential role of the interferon pathway in the development and progression of castration-resistant prostate cancer. This research offers new insights into potential therapeutic approaches for advanced prostate cancer in both dogs and humans. [Extracted from the article]

Researchers at New York University Grossman School of Medicine conducted a study on a sleep and health improvement program (SHIP) for prostate cancer survivors and caregivers. The program aimed to promote healthy sleep, eating, and physical activity. Results showed improvements in sleep hygiene, healthy eating habits, and fatigue-related problems, with positive feedback from participants. The study concluded that a web-based program like SHIP is feasible and acceptable, with plans for a randomized controlled trial to further test its effectiveness. [Extracted from the article]

Researchers from Universita Cattolica del Sacro Cuore in Rome, Italy, conducted a study on the prognostic impact of the H19/cell adhesion molecules circuitry on prostate cancer biopsies. The study aimed to identify potential biomarkers for predicting disease progression in prostate cancer patients. By analyzing specific markers within this pathway, researchers developed a composite biomarker score called the "BioScore" to predict metastasis risk at the biopsy stage, offering opportunities for early intervention and personalized treatment strategies. This research contributes valuable insights to the field of personalized medicine and oncology. [Extracted from the article]

Researchers at Northwestern University conducted a phase 2 trial, BRCAAway, to evaluate the efficacy of abiraterone, olaparib, or a combination of both as first-line therapy for metastatic castration-resistant prostate cancer with DNA repair defects. The study included patients with BRCA1/2 or ATM mutations and found that the combination of abiraterone and olaparib demonstrated longer progression-free survival compared to either agent alone or sequentially. The research was well-tolerated and concluded that in patients with these mutations, the combination therapy showed promising results. The study was funded by AstraZeneca and Merck Sharp & Dohme LLC. [Extracted from the article]

A recent study conducted at Memorial Sloan-Kettering Cancer Center in New York City compared the efficacy of Lu-177-PSMA-617 and a change in androgen receptor pathway inhibitor therapy for taxane-naive patients with metastatic castration-resistant prostate cancer. The study found that Lu-177-PSMA-617 prolonged radiographic progression-free survival compared to the ARPI change, with a favorable safety profile. This research, funded by Novartis and the NIH/NCI Cancer Center Support Grant, provides new insights into potential treatment alternatives for patients with progressive metastatic castration-resistant prostate cancer. [Extracted from the article]

A study conducted by researchers at the University of Cordoba and IMIBIC evaluated the protective effects of fermented black garlic extract on prostate cancer using human prostate cancer cell models in the laboratory. The extract was found to reduce tumor aggressiveness parameters, including cell proliferation, without affecting normal prostate cells. The researchers identified key signaling pathways related to inflammation that were altered by the extract, suggesting its potential as a dietary supplement to mitigate adverse events in prostate cancer progression. Further studies are planned to assess the preventive effects of the compound in individuals with a family history of prostate cancer or those already diagnosed with the disease. [Extracted from the article]